US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Definium Therapeutics

39.72

-1.2600-3.07%

Post-market: 39.54-0.1828-0.46%19:58 EDT

Volume:2.69M

Turnover:107.23M

Market Cap:5.34B

PE:-11.41

High:41.35

Open:40.61

Low:39.16

Close:40.98

52wk High:49.70

52wk Low:8.70

Shares:134.37M

Float Shares:131.11M

Volume Ratio:1.72

T/O Rate:2.05%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.4823

EPS(LYR):-2.0600

ROE:-64.09%

ROA:-20.64%

PB:5.81

PE(LYR):-19.28

Loading ...

Overview Company News Filings

Definium Q1 FY26 net loss widens to $77.1 million; R&D expense jumps 77.5% to $41.5 million

BRIEF-Definium Therapeutics Inc Q1 Net Income USD -77.098 Million

Definium Therapeutics to report first-quarter results in webcast update

Definium Therapeutics Inc : Needham Raises Target Price to $38 From $28

THOMSON REUTERS

U.S. RESEARCH ROUNDUP-Alphabet, Amazon, Meta

A Look At Definium Therapeutics (DFTX) Valuation After Recent Share Price Volatility

Simply Wall St.

Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX) and Cabaletta Bio (CABA)

Definium Therapeutics (DFTX): Late-Stage DT120 Psychedelic Pipeline and Multiple Near-Term Catalysts Support Buy Rating and $61 Target

Psychedelic Pharma Stocks Are Riding High. Past Cannabis Returns Are a Reality Check. -- Barrons.com

Enveric Biosciences up 3%, U.S.‑Listed Shares of Cybin Rise 4.5%

THOMSON REUTERS

Definium Therapeutics Adds 0.4%, Compass Pathways Rises 5.5%

THOMSON REUTERS

Psychedelic Drug Developers Rise After US FDA Moves to Fast-Track Drugs After Trump Order

THOMSON REUTERS

Oppenheimer Adjusts Definium Therapeutics PT to $40 From $25, Maintains Outperform Rating

MT Newswires Live

Definium Therapeutics price target raised to $40 from $25 at Oppenheimer

Definium Therapeutics : Oppenheimer Raises Target Price to $40 From $25

THOMSON REUTERS

Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF), Zymeworks (ZYME) and Definium Therapeutics (DFTX)

Piper Sandler Sticks to Its Buy Rating for Definium Therapeutics (DFTX)

U.S. RESEARCH ROUNDUP-CME Group, GE Vernova, Texas Instruments

Definium Therapeutics: Strengthened Investment Case and Multi-Indication Upside Ahead of Key Phase 3 Readouts

Definium plans Phase 3 Haven trial of DT120 ODT in PTSD for 2027 start

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/DFTX/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DFTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DFTX\",,,,,undefined,":{"symbol":"DFTX","market":"US","secType":"STK","nameCN":"Definium Therapeutics","latestPrice":39.72,"timestamp":1788206400000,"preClose":40.98,"halted":0,"volume":2692609,"hourTrading":{"tag":"盘后","latestPrice":39.5372,"preClose":39.72,"latestTime":"19:58 EDT","volume":324533,"amount":12889776.80648,"timestamp":1788220716027,"change":-0.1828,"changeRate":-0.004602,"amplitude":0.012588},"delay":0,"changeRate":-0.03074670571010244,"floatShares":131114280,"shares":134366950,"eps":-3.482311,"marketStatus":"Not Yet Opened","change":-1.26,"latestTime":"08-31 16:00:00 EDT","open":40.61,"high":41.345,"low":39.16,"amount":107228737.54624,"amplitude":0.053319,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.482311,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788249600000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":40.98,"preHourTrading":{"tag":"盘前","latestPrice":40.84,"preClose":40.98,"latestTime":"09:29 EDT","volume":3203,"amount":130501.552214,"timestamp":1788182970141,"change":-0.14,"changeRate":-0.003416,"amplitude":0.016593},"postHourTrading":{"tag":"盘后","latestPrice":39.5372,"preClose":39.72,"latestTime":"19:58 EDT","volume":324533,"amount":12889776.80648,"timestamp":1788220716027,"change":-0.1828,"changeRate":-0.004602,"amplitude":0.012588},"volumeRatio":1.722,"impliedVol":0.901,"impliedVolPercentile":0.4551},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DFTX\",,,,,undefined,":{"symbol":"DFTX","floatShares":131114280,"roa":"-20.64%","roe":"-64.09%","lyrEps":-2.059999,"volumeRatio":1.722,"shares":134366950,"dividePrice":0,"high":41.345,"amplitude":0.053319,"preClose":40.98,"low":39.16,"week52Low":8.7,"pbRate":"5.81","week52High":49.7,"institutionHeld":0,"latestPrice":39.72,"eps":-3.482311,"divideRate":0,"volume":2692609,"delay":0,"ttmEps":-3.482311,"open":40.61,"prevYearClose":13.39,"prevWeekClose":40.98,"prevMonthClose":43.52,"prevQuarterClose":47.04,"fiveDayClose":43.27,"twentyDayClose":41.79,"sixtyDayClose":24.59},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DFTX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"DFTX","fiscalQuarterEnding":"2026/06","expectedEps":-0.55,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"post","actualEps":-1.44},{"market":"US","date":"2026-05-07","symbol":"DFTX","fiscalQuarterEnding":"2026/03","expectedEps":-0.47,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"post","actualEps":-0.71},{"market":"US","date":"2026-02-26","symbol":"DFTX","fiscalQuarterEnding":"2025/12","expectedEps":-0.45,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1772082000000,"reportTimeType":"post","actualEps":-0.45}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DFTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DFTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3889,"buy":0.6111,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6111,"analysts":18,"updateTime":1787198400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/DFTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"DFTX","date":"2026-08-28","current":-11.406218,"percent":0.25974,"low":-27.074722,"twenty":-17.426666,"median":-11.092954,"eighty":-9.887379,"high":-8.802064,"avg":-13.888901,"sd":5.552967,"marketCap":5887959749},"quantilePoints":[{"date":"2026-01-16","current":-9.013032,"twenty":-8.970838,"median":-8.907548,"eighty":-8.844258,"marketCap":1515072711},{"date":"2026-01-23","current":-9.944809,"twenty":-9.944809,"median":-9.423248,"eighty":-8.819645,"marketCap":1671702464},{"date":"2026-01-30","current":-10.103035,"twenty":-10.103035,"median":-9.868626,"eighty":-9.013032,"marketCap":1698299969},{"date":"2026-02-06","current":-9.522872,"twenty":-10.196799,"median":-9.918438,"eighty":-9.522872,"marketCap":1600775783},{"date":"2026-02-13","current":-9.511152,"twenty":-10.179218,"median":-9.944809,"eighty":-9.522872,"marketCap":1598805598},{"date":"2026-02-20","current":-10.120616,"twenty":-10.18039,"median":-9.944809,"eighty":-9.520528,"marketCap":1701255248},{"date":"2026-02-27","current":-9.267085,"twenty":-10.187422,"median":-9.96239,"eighty":-9.520528,"marketCap":1703225433},{"date":"2026-03-06","current":-9.519961,"twenty":-10.18039,"median":-9.903787,"eighty":-9.502065,"marketCap":1749702163},{"date":"2026-03-13","current":-9.753213,"twenty":-10.18039,"median":-9.918437,"eighty":-9.518199,"marketCap":1792572359},{"date":"2026-03-20","current":-10.122078,"twenty":-10.169841,"median":-9.903787,"eighty":-9.52229,"marketCap":1860367087},{"date":"2026-03-27","current":-10.273963,"twenty":-10.169841,"median":-9.918437,"eighty":-9.559599,"marketCap":1888282563},{"date":"2026-04-02","current":-11.174427,"twenty":-10.181562,"median":-9.918437,"eighty":-9.550417,"marketCap":2053781457},{"date":"2026-04-10","current":-11.619234,"twenty":-10.247114,"median":-9.944809,"eighty":-9.57529,"marketCap":2135533923},{"date":"2026-04-17","current":-12.18338,"twenty":-10.396104,"median":-9.980506,"eighty":-9.589394,"marketCap":2239219977},{"date":"2026-04-24","current":-12.617338,"twenty":-11.167918,"median":-10.038572,"eighty":-9.618687,"marketCap":2318978480},{"date":"2026-05-01","current":-11.86876,"twenty":-11.389236,"median":-10.10442,"eighty":-9.643639,"marketCap":2181395062},{"date":"2026-05-08","current":-13.767387,"twenty":-11.71579,"median":-10.122078,"eighty":-9.665202,"marketCap":2530349365},{"date":"2026-05-15","current":-9.802755,"twenty":-11.643102,"median":-10.113211,"eighty":-9.689477,"marketCap":2328575817},{"date":"2026-05-22","current":-10.399644,"twenty":-11.570414,"median":-10.105791,"eighty":-9.636028,"marketCap":2470362634},{"date":"2026-05-29","current":-10.780735,"twenty":-11.483622,"median":-10.120616,"eighty":-9.642537,"marketCap":2560888064},{"date":"2026-06-05","current":-11.290386,"twenty":-11.393576,"median":-10.145827,"eighty":-9.660184,"marketCap":2681952193},{"date":"2026-06-12","current":-11.069996,"twenty":-11.344489,"median":-10.179218,"eighty":-9.68473,"marketCap":2629600138},{"date":"2026-06-18","current":-11.216923,"twenty":-11.349156,"median":-10.196799,"eighty":-9.702279,"marketCap":2664501508},{"date":"2026-06-26","current":-20.565124,"twenty":-11.510745,"median":-10.247973,"eighty":-9.723056,"marketCap":4885101210},{"date":"2026-07-02","current":-24.252692,"twenty":-11.77112,"median":-10.299843,"eighty":-9.753213,"marketCap":5761057223},{"date":"2026-07-10","current":-27.074722,"twenty":-12.069466,"median":-10.333633,"eighty":-9.796609,"marketCap":6431410656},{"date":"2026-07-17","current":-24.643864,"twenty":-12.519698,"median":-10.492938,"eighty":-9.802755,"marketCap":5853977501},{"date":"2026-07-24","current":-23.990048,"twenty":-12.931958,"median":-10.537388,"eighty":-9.812883,"marketCap":5698667894},{"date":"2026-07-31","current":-24.861803,"twenty":-14.440728,"median":-10.67054,"eighty":-9.817222,"marketCap":5905747370},{"date":"2026-08-07","current":-17.312135,"twenty":-19.588062,"median":-10.789918,"eighty":-9.824231,"marketCap":6124773739},{"date":"2026-08-14","current":-16.673146,"twenty":-17.887875,"median":-10.831241,"eighty":-9.831914,"marketCap":5898709105},{"date":"2026-08-21","current":-17.242844,"twenty":-17.526933,"median":-11.058518,"eighty":-9.861594,"marketCap":6100259530},{"date":"2026-08-28","current":-16.642763,"twenty":-17.426666,"median":-11.092954,"eighty":-9.887379,"marketCap":5887959749}],"updateTime":1788232076598},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DFTX\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2633176393","title":"Definium Q1 FY26 net loss widens to $77.1 million; R&D expense jumps 77.5% to $41.5 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633176393","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633176393?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:02","pubTimestamp":1778184153,"startTime":"0","endTime":"0","summary":"Definium Therapeutics posted a net loss of USD 77.1 million, widening from USD 23.3 million a year earlier; loss per share deepened to USD 0.71 from USD 0.27.Operating loss widened to USD 59.2 million from USD 32.2 million as R&D expenses climbed to USD 41.5 million from USD 23.4 million.Cash, cash equivalents, and investments fell to USD 373.4 million from USD 411.6 million at Dec. 31, 2025; cash runway expected to extend into 2028.Enrollment completed for Phase 3 Emerge in MDD and Phase 3 Voyage in GAD, with topline data expected in late 2Q 2026 and early 3Q 2026.Panorama GAD target enrollment updated to 200 with screening closed, pushing topline data to late 3Q 2026; Phase 3 PTSD study Haven planned for 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, inves","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL9NBlDx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633864176","title":"BRIEF-Definium Therapeutics Inc Q1 Net Income USD -77.098 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633864176","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633864176?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:01","pubTimestamp":1778184105,"startTime":"0","endTime":"0","summary":"BRIEF-Definium Therapeutics Inc Q1 Net Income USD -77.098 Million\n\n\nMay 07 (Reuters) - Definium Therapeutics Inc Q1 operating expenses USD 59.22 million.\n\nQ1 EPS USD -0.71\nQ1 basic EPS USD -0.71\nQ1 income from operations USD -59.22 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLXB42F30:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632766536","title":"Definium Therapeutics to report first-quarter results in webcast update","url":"https://stock-news.laohu8.com/highlight/detail?id=2632766536","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632766536?lang=en_us&edition=fundamental","pubTime":"2026-05-01 04:02","pubTimestamp":1777579354,"startTime":"0","endTime":"0","summary":"Definium Therapeutics will host live webcast May 7, 2026 at 4:30 p.m. EDT to report first-quarter 2026 financial results.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on April 30, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDLbkzGLQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631935635","title":"Definium Therapeutics Inc : Needham Raises Target Price to $38 From $28","url":"https://stock-news.laohu8.com/highlight/detail?id=2631935635","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631935635?lang=en_us&edition=fundamental","pubTime":"2026-04-30 19:04","pubTimestamp":1777547091,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nFWN41D102:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631500039","title":"U.S. RESEARCH ROUNDUP-Alphabet, Amazon, Meta","url":"https://stock-news.laohu8.com/highlight/detail?id=2631500039","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631500039?lang=en_us&edition=fundamental","pubTime":"2026-04-30 15:23","pubTimestamp":1777533789,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Alphabet, Amazon, Meta April 30 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Alphabet, Amazon a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nL4N41D0U8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBZ","BIIB","CHRW","CRS","AMZZ","BLKB","APEI","AMP","GOOX","BEG","CMG","CELH","BG","AVT","BHE","DFTX","CEGX","ALGN","AMR","AMZN","CTSH","APH","CEG","GOOY","GOU","BRO","CCB","CHEF","GOOP","CAKE","AFL","CVNA","EAT","AMZP","AVY","GOOGL","AMZY","ABBV","CSGP","ABG","CNK","DAN","GOOG","APPN","BE","ASH","USAW.SI","GOOW","ADP","AMZD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631527475","title":"A Look At Definium Therapeutics (DFTX) Valuation After Recent Share Price Volatility","url":"https://stock-news.laohu8.com/highlight/detail?id=2631527475","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631527475?lang=en_us&edition=fundamental","pubTime":"2026-04-30 04:13","pubTimestamp":1777493620,"startTime":"0","endTime":"0","summary":"What recent moves in Definium Therapeutics stock might mean for investors\nDefinium Therapeutics (DFTX) has drawn fresh attention after recent share price swings, with a 1 day gain of 1.38% contrasting with a 10.78% decline over the past week and stronger longer term returns.\nSee our latest analysis for Definium Therapeutics.\nAt a share price of $21.27, Definium Therapeutics shows mixed momentum, with a recent 7 day share price return of a 10.78% decline, a 55.94% year to date share price...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dftx/definium-therapeutics/news/a-look-at-definium-therapeutics-dftx-valuation-after-recent","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dftx/definium-therapeutics/news/a-look-at-definium-therapeutics-dftx-valuation-after-recent","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631584602","title":"Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX) and Cabaletta Bio (CABA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2631584602","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631584602?lang=en_us&edition=fundamental","pubTime":"2026-04-29 00:40","pubTimestamp":1777394431,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Definium Therapeutics (DFTX) and Cabaletta Bio (CABA...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-definium-therapeutics-dftx-and-cabaletta-bio-caba-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-definium-therapeutics-dftx-and-cabaletta-bio-caba-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX","BK4581","BK4137","HCSG","LU0128526141.USD","XBI","CABA","BK4585","XLV","BK4588","LU0029874061.USD","BK4139","BK4007","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630827395","title":"Definium Therapeutics (DFTX): Late-Stage DT120 Psychedelic Pipeline and Multiple Near-Term Catalysts Support Buy Rating and $61 Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2630827395","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630827395?lang=en_us&edition=fundamental","pubTime":"2026-04-25 03:45","pubTimestamp":1777059925,"startTime":"0","endTime":"0","summary":"Analyst Justin Walsh from JonesTrading reiterated a Buy rating on Definium Therapeutics and keeping the price target at $61.00. Justin Walsh has gi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/definium-therapeutics-dftx-late-stage-dt120-psychedelic-pipeline-and-multiple-near-term-catalysts-support-buy-rating-and-61-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/definium-therapeutics-dftx-late-stage-dt120-psychedelic-pipeline-and-multiple-near-term-catalysts-support-buy-rating-and-61-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630825711","title":"Psychedelic Pharma Stocks Are Riding High. Past Cannabis Returns Are a Reality Check. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2630825711","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630825711?lang=en_us&edition=fundamental","pubTime":"2026-04-24 23:58","pubTimestamp":1777046280,"startTime":"0","endTime":"0","summary":"I've never gone on one of those self-discovery trips where an Amazonian shaman administers hallucinogenic brew made from the ayahuasca vine. But I did overshare here recently about my Atomic Fireball habit, and while they're usually individually wrapped, I found a packet with two the other day, so I doubled up. During the deep introspection that followed, a spirit guide whispered into my ear: Are psychedelic stocks overpriced?I didn't answer; I have a hard enough time figuring out momentum stocks in this dimension. But he might have been on to something.This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATAI","MJ","BK4139","CMPS","BK4007","TOKE","DFTX","CNBS","MSOS","WEED","YOLO","MSOX","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629842685","title":"Enveric Biosciences up 3%, U.S.‑Listed Shares of Cybin Rise 4.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629842685","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629842685?lang=en_us&edition=fundamental","pubTime":"2026-04-24 21:32","pubTimestamp":1777037539,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nL4N4171CD:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GHRS","CMPS","BK4539","ENVB","BK4139","DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629842681","title":"Definium Therapeutics Adds 0.4%, Compass Pathways Rises 5.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629842681","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629842681?lang=en_us&edition=fundamental","pubTime":"2026-04-24 21:32","pubTimestamp":1777037538,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nL4N4171CD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GHRS","BK4539","BK4007","CMPS","BK4139","ENVB","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629426838","title":"Psychedelic Drug Developers Rise After US FDA Moves to Fast-Track Drugs After Trump Order","url":"https://stock-news.laohu8.com/highlight/detail?id=2629426838","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629426838?lang=en_us&edition=fundamental","pubTime":"2026-04-24 21:32","pubTimestamp":1777037537,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nL4N4171CD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GHRS","BK4539","BK4007","CMPS","BK4139","ENVB","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629830008","title":"Oppenheimer Adjusts Definium Therapeutics PT to $40 From $25, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2629830008","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629830008?lang=en_us&edition=fundamental","pubTime":"2026-04-23 22:02","pubTimestamp":1776952941,"startTime":"0","endTime":"0","summary":"Definium Therapeutics, Inc. (DFTX) has an average rating of Buy and mean price target of $38.87, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OPY","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629832855","title":"Definium Therapeutics price target raised to $40 from $25 at Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2629832855","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629832855?lang=en_us&edition=fundamental","pubTime":"2026-04-23 20:59","pubTimestamp":1776949189,"startTime":"0","endTime":"0","summary":"Oppenheimer raised the firm’s price target on Definium Therapeutics (DFTX) to $40 from $25 and keeps an Outperform rating on the shares. The firm a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/definium-therapeutics-price-target-raised-to-40-from-25-at-oppenheimer-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/definium-therapeutics-price-target-raised-to-40-from-25-at-oppenheimer-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OPY","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629831820","title":"Definium Therapeutics : Oppenheimer Raises Target Price to $40 From $25","url":"https://stock-news.laohu8.com/highlight/detail?id=2629831820","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629831820?lang=en_us&edition=fundamental","pubTime":"2026-04-23 20:23","pubTimestamp":1776946992,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nAZN4SSCNL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629835592","title":"Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF), Zymeworks (ZYME) and Definium Therapeutics (DFTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2629835592","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629835592?lang=en_us&edition=fundamental","pubTime":"2026-04-23 19:21","pubTimestamp":1776943291,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sanofi (SNYNF), Zymeworks (ZYME) and Definium Therap...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-sanofi-othersnynf-zymeworks-zyme-and-definium-therapeutics-dftx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-sanofi-othersnynf-zymeworks-zyme-and-definium-therapeutics-dftx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","BK4137","HCSG","XBI","XLV","LABU","BK4588","DFTX","BK4007","LU0128526141.USD","ZYME","BK4581","BK4139","SNYNF","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629835596","title":"Piper Sandler Sticks to Its Buy Rating for Definium Therapeutics (DFTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2629835596","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629835596?lang=en_us&edition=fundamental","pubTime":"2026-04-23 19:20","pubTimestamp":1776943241,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst David Amsellem reiterated a Buy rating on Definium Therapeutics today and set a price target of $49.00. Amsellem covers the H...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-its-buy-rating-for-definium-therapeutics-dftx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-its-buy-rating-for-definium-therapeutics-dftx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629831298","title":"U.S. RESEARCH ROUNDUP-CME Group, GE Vernova, Texas Instruments","url":"https://stock-news.laohu8.com/highlight/detail?id=2629831298","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629831298?lang=en_us&edition=fundamental","pubTime":"2026-04-23 15:46","pubTimestamp":1776930366,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-CME Group, GE Vernova, Texas InstrumentsApril 23 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including C","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nL4N4160NQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKAM","GEVX","BWA","CBRE","COF","MMM","OZK","ASGN","LNG","AMZY","CALX","BKU","DLR","ELF","AMZZ","DTM","CAR","AZYY","CSX","ASTI","DAN","CRGY","ABBV","AMZU","T","BSX","GEVG","CLX","CHEF","CSGP","ELV","EFOR","CME","BIIB","CCS","GEV","AVB","BA","AMZP","DFTX","TXN","COTY","AMZD","CHTR","CPAY","CYH","EWBC","CL","CPNG","CPT","AMZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629553076","title":"Definium Therapeutics: Strengthened Investment Case and Multi-Indication Upside Ahead of Key Phase 3 Readouts","url":"https://stock-news.laohu8.com/highlight/detail?id=2629553076","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629553076?lang=en_us&edition=fundamental","pubTime":"2026-04-23 05:55","pubTimestamp":1776894925,"startTime":"0","endTime":"0","summary":"Needham analyst Ami Fadia maintained a Buy rating on Definium Therapeutics today and set a price target of $28.00. Ami Fadia has given his Buy rati...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/definium-therapeutics-strengthened-investment-case-and-multi-indication-upside-ahead-of-key-phase-3-readouts-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/definium-therapeutics-strengthened-investment-case-and-multi-indication-upside-ahead-of-key-phase-3-readouts-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629207810","title":"Definium plans Phase 3 Haven trial of DT120 ODT in PTSD for 2027 start","url":"https://stock-news.laohu8.com/highlight/detail?id=2629207810","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629207810?lang=en_us&edition=fundamental","pubTime":"2026-04-23 04:36","pubTimestamp":1776890211,"startTime":"0","endTime":"0","summary":"Definium outlined near-term catalysts for DT120 ODT, with pivotal topline results scheduled for late 2Q 2026 through late 3Q 2026, meaning no new results were presented.MDD program remains central to value creation, with Emerge topline data expected late 2Q 2026.GAD readouts remain on track, with Voyage expected early 3Q 2026; Panorama timing shifted to late 3Q 2026 following a blinded reassessment of enrollment needs.Pipeline scope expanded into PTSD, with Phase 3 Haven initiation planned for 2027.Company positioned DT120 ODT as a scalable commercial franchise, targeting broad adoption across care settings ahead of potential regulatory filings.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL1JM1Tg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":200,"code":"91000000","status":"200"}]}}